BEDFORD, Mass.--(BUSINESS WIRE)--Resolvyx Pharmaceuticals, Inc., the leading resolvin therapeutics company, today announced that a research team led by a Resolvyx scientific advisor and a company co-founder has demonstrated that the resolvin E1 (RvE1) effectively suppresses IL-23 and IL-17, two key inflammatory mediators of chronic inflammatory disease, in a preclinical model of asthma. RvE1 is the active ingredient in RX-10001, one of Resolvyx’s leading clinical candidates. The paper, titled “Resolvin E1 regulates interleukin 23, interferon-d and lipoxin A4 to promote the resolution of allergic airway inflammation,” published in the journal Nature Immunology.
